Evogene Announces Filing of Annual Report on Form 20-F
Evogene Announces Filing of Annual Report on Form 20-F
REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission.
以色列雷霍沃特，2024年3月28日 /PRNewswire/ — 領先的計算生物學公司Evogene Ltd.（納斯達克股票代碼：EVGN）（TASE：EVGN）今天宣佈，已向美國證券交易委員會提交了截至2023年12月31日財年的20-F表年度報告。
The Annual Report on Form 20-F can be accessed on the Company's investor relations website and on the SEC's website at The Company's security holders may request a hard copy of the Annual Report free of charge by visiting the Contact Us page of the Company's website.
可以在公司的投資者關係網站上訪問20-F表格的年度報告，也可以在美國證券交易委員會的網站上訪問。公司的證券持有人可以通過訪問公司網站的 “聯繫我們” 頁面免費索取年度報告的紙質副本。
About Evogene:
關於 Evogene：
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.
Evogene Ltd.（納斯達克股票代碼：EVGN，TASE：EVGN）是一家利用大數據和人工智能的計算生物學公司，旨在通過利用尖端技術來提高成功概率，同時減少開發時間和成本，從而徹底改變基於生命科學的產品的開發。
Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene 建立了三種獨特的技術引擎- 微升壓 AI， ChemPass AI 和 生成器人工智能。每個技術引擎都專注於發現和開發基於以下核心成分之一的產品：微生物（MicroBoost）、小分子（ChemPass AI）和遺傳元素（生成器人工智能)。
Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:
Evogene利用其技術引擎通過戰略合作伙伴關係和合作開發產品，其五家子公司包括：
1. Biomica Ltd. () developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
1。 Biomica 有限公司 () 開發和推進基於微生物組的新型療法，以治療人類疾病 微增強人工智能;
2. Lavie Bio Ltd. () - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
2。 Lavie Bio 有限公司 ()-開發和商業推進基於微生物組的農業生物製劑，由 微增強人工智能;
3. AgPlenus Ltd. () -developing next generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
3。 agPlenus 有限公司 ()-開發下一代農業化學品，以實現有效和可持續的作物保護 ChemPass AI;
4. Canonic Ltd. () – developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by GeneRator AI; and
4。 Canonic 有限公司 () — 基於解碼植物遺傳學開發醫用大麻產品，以優化治療效果 生成器人工智能； 和
5. Casterra Ag Ltd. ()– developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.
5。 Casterra Ag 有限公司 () — 以工業規模爲生物燃料和其他由以下驅動的行業開發和銷售產量高、含油量高的優質蓖麻種子品種 生成器人工智能。
For more information, please visit: .
想要查詢更多的信息, 請訪問:.
Contact
聯繫我們
Rachel Pomerantz Gerber
雷切爾·波美蘭茲·格伯
Head of Investor Relations at Evogene
Evogene 投資者關係主管
[email protected]
[電子郵件保護]
Tel: +972-8-9311901
電話：+972-8-9311901
Logo -
徽標-
SOURCE Evogene
來源 Evogene
譯文內容由第三人軟體翻譯。